FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2051255335> ?p ?o ?g. }

• W2051255335 endingPage "323" @default.
• W2051255335 startingPage "317" @default.
• W2051255335 abstract "Symptomatic intracranial hemorrhage (sICH) is a known complication following administration of intravenous tissue plasminogen activator (IV tPA) for acute ischemic stroke. sICH results in high rates of death or long-term disability. Our ability to predict its occurrence is important in clinical decision making and when counseling families. The initial National Institute of Neurological Disorders and Stroke (NINDS) investigators developed a list of relative contraindications to IV tPA meant to decrease the risk of subsequent sICH. To date, the impact of renal impairment has not been well studied. In the current study we evaluate the potential association between renal impairment and post-tPA intracranial hemorrhage (ICH). Admission serum creatinine and estimated glomerular filtration rate (eGFR) were recorded in 224 patients presenting within 4.5 hours from symptom onset and treated with IV tPA based on NINDS criteria. Neuroimaging was obtained 1 day post-tPA and for any change in neurologic status to evaluate for ICH. Images were retrospectively evaluated for hemorrhage by a board-certified neuroradiologist and 2 reviewers blinded to the patient’s neurologic status. Medical records were reviewed retrospectively for evidence of neurologic decline indicating a “symptomatic” hemorrhage. sICH was defined as subjective clinical deterioration (documented by the primary neurology team) and hemorrhage on neuroimaging that was felt to be the most likely cause. Renal impairment was evaluated using both serum creatinine and eGFR in a number of ways: 1) continuous creatinine; 2) any renal impairment by creatinine (serum creatinine >1.0 mg/dL); 3) continuous eGFR; and 4) any renal impairment by eGFR (eGFR <60 mL/min per 1.73 m2). Student paired t tests, Fisher exact tests, and multivariable logistic regression (adjusted for demographics and vascular risk factors) were used to evaluate the relationship between renal impairment and ICH. Fifty-seven (25%) of the 224 patients had some evidence of hemorrhage on neuroimaging. The majority of patients were asymptomatic. Renal impairment (defined by serum creatinine >1.0 mg/dL) was not associated with combined symptomatic and asymptomatic intracranial bleeding (p = 0.359); however, there was an adjusted 5.5-fold increased odds of sICH when creatinine was >1.0 mg/dL (95% confidence interval, 1.08–28.39), and the frequency of sICH for patients with elevated serum creatinine was 10.6% (12/113), versus 1.8% (2/111) in those with normal renal function (p = 0.010). Our study suggests that renal impairment is associated with higher risk of sICH after administration of IV tPA. As IV tPA is an important and effective treatment for acute ischemic stroke, a multicenter study is needed to determine whether the observation that renal dysfunction is associated with sICH from this retrospective study holds true in a larger prospective trial." @default.
• W2051255335 created "2016-06-24" @default.
• W2051255335 creator A5005636192 @default.
• W2051255335 creator A5040599069 @default.
• W2051255335 creator A5052488350 @default.
• W2051255335 creator A5070350395 @default.
• W2051255335 creator A5074582528 @default.
• W2051255335 date "2013-11-01" @default.
• W2051255335 modified "2023-10-17" @default.
• W2051255335 title "Serum Creatinine May Indicate Risk of Symptomatic Intracranial Hemorrhage After Intravenous Tissue Plasminogen Activator (IV tPA)" @default.
• W2051255335 cites W1972179384 @default.
• W2051255335 cites W1974335674 @default.
• W2051255335 cites W1976787367 @default.
• W2051255335 cites W2002160967 @default.
• W2051255335 cites W2006647499 @default.
• W2051255335 cites W2007676812 @default.
• W2051255335 cites W2036789134 @default.
• W2051255335 cites W2050900880 @default.
• W2051255335 cites W2054077136 @default.
• W2051255335 cites W2055864845 @default.
• W2051255335 cites W2108506714 @default.
• W2051255335 cites W2113115892 @default.
• W2051255335 cites W2117168487 @default.
• W2051255335 cites W2127985968 @default.
• W2051255335 cites W2129139440 @default.
• W2051255335 cites W2153595356 @default.
• W2051255335 cites W2159233098 @default.
• W2051255335 cites W2171417940 @default.
• W2051255335 cites W2180318774 @default.
• W2051255335 cites W2292308933 @default.
• W2051255335 cites W4250104750 @default.
• W2051255335 cites W4292339830 @default.
• W2051255335 doi "https://doi.org/10.1097/md.0000000000000006" @default.
• W2051255335 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4442012" @default.
• W2051255335 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24145699" @default.
• W2051255335 hasPublicationYear "2013" @default.
• W2051255335 type Work @default.
• W2051255335 sameAs 2051255335 @default.
• W2051255335 citedByCount "23" @default.
• W2051255335 countsByYear W20512553352014 @default.
• W2051255335 countsByYear W20512553352015 @default.
• W2051255335 countsByYear W20512553352016 @default.
• W2051255335 countsByYear W20512553352017 @default.
• W2051255335 countsByYear W20512553352019 @default.
• W2051255335 countsByYear W20512553352020 @default.
• W2051255335 countsByYear W20512553352021 @default.
• W2051255335 countsByYear W20512553352022 @default.
• W2051255335 crossrefType "journal-article" @default.
• W2051255335 hasAuthorship W2051255335A5005636192 @default.
• W2051255335 hasAuthorship W2051255335A5040599069 @default.
• W2051255335 hasAuthorship W2051255335A5052488350 @default.
• W2051255335 hasAuthorship W2051255335A5070350395 @default.
• W2051255335 hasAuthorship W2051255335A5074582528 @default.
• W2051255335 hasBestOaLocation W20512553351 @default.
• W2051255335 hasConcept C118552586 @default.
• W2051255335 hasConcept C126322002 @default.
• W2051255335 hasConcept C127413603 @default.
• W2051255335 hasConcept C141071460 @default.
• W2051255335 hasConcept C159641895 @default.
• W2051255335 hasConcept C16568411 @default.
• W2051255335 hasConcept C2776572282 @default.
• W2051255335 hasConcept C2777094939 @default.
• W2051255335 hasConcept C2777736543 @default.
• W2051255335 hasConcept C2779581417 @default.
• W2051255335 hasConcept C2780306776 @default.
• W2051255335 hasConcept C2780645631 @default.
• W2051255335 hasConcept C500558357 @default.
• W2051255335 hasConcept C71924100 @default.
• W2051255335 hasConcept C78519656 @default.
• W2051255335 hasConceptScore W2051255335C118552586 @default.
• W2051255335 hasConceptScore W2051255335C126322002 @default.
• W2051255335 hasConceptScore W2051255335C127413603 @default.
• W2051255335 hasConceptScore W2051255335C141071460 @default.
• W2051255335 hasConceptScore W2051255335C159641895 @default.
• W2051255335 hasConceptScore W2051255335C16568411 @default.
• W2051255335 hasConceptScore W2051255335C2776572282 @default.
• W2051255335 hasConceptScore W2051255335C2777094939 @default.
• W2051255335 hasConceptScore W2051255335C2777736543 @default.
• W2051255335 hasConceptScore W2051255335C2779581417 @default.
• W2051255335 hasConceptScore W2051255335C2780306776 @default.
• W2051255335 hasConceptScore W2051255335C2780645631 @default.
• W2051255335 hasConceptScore W2051255335C500558357 @default.
• W2051255335 hasConceptScore W2051255335C71924100 @default.
• W2051255335 hasConceptScore W2051255335C78519656 @default.
• W2051255335 hasIssue "6" @default.
• W2051255335 hasLocation W20512553351 @default.
• W2051255335 hasLocation W20512553352 @default.
• W2051255335 hasLocation W20512553353 @default.
• W2051255335 hasLocation W20512553354 @default.
• W2051255335 hasLocation W20512553355 @default.
• W2051255335 hasOpenAccess W2051255335 @default.
• W2051255335 hasPrimaryLocation W20512553351 @default.
• W2051255335 hasRelatedWork W1972008951 @default.
• W2051255335 hasRelatedWork W2022175645 @default.
• W2051255335 hasRelatedWork W205404821 @default.
• W2051255335 hasRelatedWork W2062751229 @default.
• W2051255335 hasRelatedWork W2064365620 @default.
• W2051255335 hasRelatedWork W2755985349 @default.

• next